Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Nervous system drugs >Drug Metabolism in Human Brain >Rivastigmine tartrate

Rivastigmine tartrate

Rivastigmine tartrate Structure
  • ₹10600 - ₹30299.18
  • Product name: Rivastigmine tartrate
  • CAS: 129101-54-8
  • MF: C18H28N2O8
  • MW: 400.42
  • EINECS:603-318-3
  • MDL Number:MFCD03700731
  • Synonyms:Rivastigimine tartrate;3-[(S)-1-(Dimethylamino)ethyl]phenyl N-Ethyl-N-methylcarbamate L-Tartrate N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate;(S)-3-(1-(diMethylaMino)ethyl)phenyl ethyl(Methyl)carbaMate (2R,3R)-2,3-dihydroxysuccinate;(S)-EthylMethylcarbaMic Acid 3-[1-(DiMethylaMino)ethyl]phenyl Ester [R-(R*,R*)]-2,3-Dihydroxybutanedioate;N-Ethyl-N-MethylcarbaMic Acid 3-[(1S)-1-(DiMethylaMino)ethyl]phenyl Ester (2R,3R)-2,3-Dihydroxybutanedioate;RivastigMine Bitartrate;RivastigMine L-Tartrate;G830 RivastigMine tartrate
4 prices
Selected condition:

Brand

  • TCI Chemicals (India)
  • Sigma-Aldrich(India)

Package

  • 50MG
  • 1G
  • 5G
  • ManufacturerTCI Chemicals (India)
  • Product numberR0093
  • Product descriptionRivastigmine L-Tartrate
  • Packaging1G
  • Price₹10600
  • Updated2022-05-26
  • Buy
  • ManufacturerTCI Chemicals (India)
  • Product numberR0093
  • Product descriptionRivastigmine L-Tartrate
  • Packaging5G
  • Price₹22200
  • Updated2022-05-26
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberSML0881
  • Product descriptionRivastigmine tartrate ≥98% (HPLC)
  • Packaging50MG
  • Price₹14267.35
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberPHR1867
  • Product descriptionRivastigmine Hydrogen Tartrate Pharmaceutical Secondary Standard; Certified Reference Material
  • Packaging1G
  • Price₹30299.18
  • Updated2022-06-14
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
TCI Chemicals (India) R0093 Rivastigmine L-Tartrate 1G ₹10600 2022-05-26 Buy
TCI Chemicals (India) R0093 Rivastigmine L-Tartrate 5G ₹22200 2022-05-26 Buy
Sigma-Aldrich(India) SML0881 Rivastigmine tartrate ≥98% (HPLC) 50MG ₹14267.35 2022-06-14 Buy
Sigma-Aldrich(India) PHR1867 Rivastigmine Hydrogen Tartrate Pharmaceutical Secondary Standard; Certified Reference Material 1G ₹30299.18 2022-06-14 Buy

Properties

Melting point :123-1250C
alpha :D20 +4.7° (c = 5 in ethanol)
storage temp. :2-8°C
solubility :H2O: soluble15mg/mL, clear
form :powder
color :white to beige
InChI :InChI=1/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/s3
InChIKey :GWHQHAUAXRMMOT-AAUFCPPMNA-N
SMILES :C1(=CC=CC([C@H](C)N(C)C)=C1)OC(=O)N(C)CC.[C@H](O)(C(=O)O)[C@@H](O)C(=O)O |&1:5,18,23,r|
CAS DataBase Reference :129101-54-8(CAS DataBase Reference)

Safety Information

Symbol(GHS): GHS hazard pictogramsGHS hazard pictograms
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H300 Fatal if swallowed Acute toxicity,oral Category 1, 2 Danger GHS hazard pictograms P264, P270, P301+P310, P321, P330,P405, P501
H411 Toxic to aquatic life with long lasting effects Hazardous to the aquatic environment, long-term hazard Category 2
Precautionary statements:
P264 Wash hands thoroughly after handling.
P264 Wash skin thouroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P301+P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P391 Collect spillage. Hazardous to the aquatic environment
P405 Store locked up.

Description

Ponatinib mono-hydrochloride is the mono-hydrochloride form of ponatinib. Ponatinib is a multi-targeted tyrosine-kinase inhibitor used for the treatment of chronic myeloid leukemia (CML), andPhiladelphia chromosome–positive (Ph+)acute lymphoblastic leukemia(ALL). Ponatinib works through directly inhibiting the Bcr-Abl tyrosine kinase protein that promotes the progression of CML. Ponatinib is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. Ponatinib can also inhibit some members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Therefore, it also has potential to treat various kinds of cancer with different targets.

Related product price